Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Quest Diagnostics Boosts Share Buyback Plan by $1 Billion

Aug. 20 (Bloomberg) -- Quest Diagnostics Inc., the biggest U.S. operator of medical labs, said its board increased a company share repurchase plan by $1 billion.

The buyback ā€œis consistent with our long-term disciplined capital deployment strategy, which includes returning the majority of our free cash flow to shareholders,ā€ Steve Rusckowski, chief executive officer of the Madison, New Jersey-based company, said today in a statement.

Quest also will use $300 million in net proceeds from the sale of royalty rights to an experimental cancer drug as part of the share buyback program. The company said July 18 it had sold royalty rights for the drug, ibrutinib, for $485 million in cash to Royalty Pharma.

Quest shares gained 1.7 percent to $59.76 in extended trading at 4:41 p.m. New York time. The company has declined 3.4 percent in the past 12 months.

To contact the reporter on this story: Robert Langreth in New York at rlangreth@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.